vs

Side-by-side financial comparison of LXP Industrial Trust (LXP) and MEDIFAST INC (MED). Click either name above to swap in a different company.

LXP Industrial Trust is the larger business by last-quarter revenue ($86.7M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, LXP Industrial Trust posted the faster year-over-year revenue change (-14.0% vs -36.9%). Over the past eight quarters, LXP Industrial Trust's revenue compounded faster (0.3% CAGR vs -34.4%).

LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

LXP vs MED — Head-to-Head

Bigger by revenue
LXP
LXP
1.2× larger
LXP
$86.7M
$75.1M
MED
Growing faster (revenue YoY)
LXP
LXP
+22.9% gap
LXP
-14.0%
-36.9%
MED
Faster 2-yr revenue CAGR
LXP
LXP
Annualised
LXP
0.3%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LXP
LXP
MED
MED
Revenue
$86.7M
$75.1M
Net Profit
$28.8M
Gross Margin
81.5%
69.4%
Operating Margin
34.6%
-10.4%
Net Margin
33.2%
Revenue YoY
-14.0%
-36.9%
Net Profit YoY
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LXP
LXP
MED
MED
Q4 25
$86.7M
$75.1M
Q3 25
$86.9M
$89.4M
Q2 25
$87.7M
$105.6M
Q1 25
$88.9M
$115.7M
Q4 24
$100.9M
$119.0M
Q3 24
$85.6M
$140.2M
Q2 24
$85.8M
$168.6M
Q1 24
$86.3M
$174.7M
Net Profit
LXP
LXP
MED
MED
Q4 25
$28.8M
Q3 25
$36.3M
$-2.3M
Q2 25
$29.1M
$2.5M
Q1 25
$19.0M
$-772.0K
Q4 24
Q3 24
$6.3M
$1.1M
Q2 24
$5.4M
$-8.2M
Q1 24
$-269.0K
$8.3M
Gross Margin
LXP
LXP
MED
MED
Q4 25
81.5%
69.4%
Q3 25
82.3%
69.5%
Q2 25
81.9%
72.6%
Q1 25
80.7%
72.8%
Q4 24
85.3%
74.1%
Q3 24
82.5%
75.4%
Q2 24
82.0%
73.2%
Q1 24
82.4%
72.8%
Operating Margin
LXP
LXP
MED
MED
Q4 25
34.6%
-10.4%
Q3 25
50.4%
-4.6%
Q2 25
33.7%
-1.0%
Q1 25
21.8%
-1.1%
Q4 24
0.6%
Q3 24
7.9%
1.5%
Q2 24
6.9%
-4.7%
Q1 24
1.0%
4.5%
Net Margin
LXP
LXP
MED
MED
Q4 25
33.2%
Q3 25
41.7%
-2.5%
Q2 25
33.2%
2.3%
Q1 25
21.4%
-0.7%
Q4 24
Q3 24
7.4%
0.8%
Q2 24
6.3%
-4.8%
Q1 24
-0.3%
4.8%
EPS (diluted)
LXP
LXP
MED
MED
Q4 25
$-1.64
Q3 25
$0.12
$-0.21
Q2 25
$0.09
$0.22
Q1 25
$0.06
$-0.07
Q4 24
$0.08
Q3 24
$0.02
$0.10
Q2 24
$0.01
$-0.75
Q1 24
$-0.01
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LXP
LXP
MED
MED
Cash + ST InvestmentsLiquidity on hand
$170.4M
$167.3M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$2.0B
$198.9M
Total Assets
$3.5B
$248.0M
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LXP
LXP
MED
MED
Q4 25
$170.4M
$167.3M
Q3 25
$229.7M
$173.5M
Q2 25
$71.0M
$162.7M
Q1 25
$70.9M
$164.6M
Q4 24
$101.8M
$162.3M
Q3 24
$55.0M
$170.0M
Q2 24
$48.7M
$163.5M
Q1 24
$293.8M
$156.4M
Total Debt
LXP
LXP
MED
MED
Q4 25
$1.4B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
LXP
LXP
MED
MED
Q4 25
$2.0B
$198.9M
Q3 25
$2.1B
$214.7M
Q2 25
$2.1B
$216.0M
Q1 25
$2.1B
$211.0M
Q4 24
$2.1B
$210.1M
Q3 24
$2.1B
$207.3M
Q2 24
$2.1B
$205.3M
Q1 24
$2.2B
$211.0M
Total Assets
LXP
LXP
MED
MED
Q4 25
$3.5B
$248.0M
Q3 25
$3.7B
$268.2M
Q2 25
$3.7B
$269.3M
Q1 25
$3.8B
$280.0M
Q4 24
$3.8B
$284.2M
Q3 24
$3.9B
$291.2M
Q2 24
$3.9B
$293.5M
Q1 24
$4.2B
$302.8M
Debt / Equity
LXP
LXP
MED
MED
Q4 25
0.66×
Q3 25
0.72×
Q2 25
0.72×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LXP
LXP
MED
MED
Operating Cash FlowLast quarter
$188.7M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
6.56×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LXP
LXP
MED
MED
Q4 25
$188.7M
$-5.3M
Q3 25
$63.5M
$12.1M
Q2 25
$44.3M
$-3.4M
Q1 25
$39.0M
$3.4M
Q4 24
$211.2M
$-4.9M
Q3 24
$64.6M
$9.1M
Q2 24
$38.5M
$13.1M
Q1 24
$38.9M
$7.3M
Free Cash Flow
LXP
LXP
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
LXP
LXP
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
LXP
LXP
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
LXP
LXP
MED
MED
Q4 25
6.56×
Q3 25
1.75×
Q2 25
1.52×
-1.36×
Q1 25
2.05×
Q4 24
Q3 24
10.18×
8.04×
Q2 24
7.09×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons